Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, announced its participation in the A.G.P. Virtual Annual Healthcare Company Showcase on May 21, 2025. CEO Frank Bedu-Addo will engage in a fireside chat from 5:20 to 5:40 p.m. ET. The virtual event will provide opportunities for one-on-one investor meetings with the PDS Biotech leadership team. A replay and transcript of the fireside chat will be available on the company's website after the event.

PDS Biotech (PDSB) reported its Q1 2025 financial results and provided clinical updates. The company has initiated the VERSATILE-003 Phase 3 trial for Versamune® HPV in HPV16-positive head and neck cancer, with Mayo Clinic sites recently added. The trial will include approximately 350 patients and received FDA Fast Track designation. Financial highlights include a net loss of $8.5 million ($0.21 per share), improved from $10.6 million in Q1 2024. R&D expenses decreased to $5.8 million from $6.7 million, while G&A expenses were $3.3 million. The company's cash balance stood at $40 million as of March 31, 2025. PDS Biotech also completed a registered direct offering raising approximately $11 million, with potential for additional $11 million from warrant exercises.

PDS Biotechnology (PDSB), a late-stage immunotherapy company focused on cancer treatment, has granted a nonstatutory stock option to a new clinical department employee. The inducement grant, issued on May 5, 2025, allows the purchase of 5,000 shares of common stock at an exercise price of $1.31 per share. The stock option follows a four-year vesting schedule, with 25% vesting after the first year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.

PDS Biotechnology (NASDAQ: PDSB) presented preclinical data on their Infectimune®-based universal flu vaccine at IMMUNOLOGY2025™. Two key presentations highlighted promising results: Dr. Andrea Sant demonstrated that Infectimune® generated a significantly higher frequency of multifunctional influenza-specific CD4 T cells with cytotoxic properties, particularly targeting lung tissue in subjects with prior flu exposure. Dr. James Allen's research showed that Infectimune®-based vaccines using COBRA antigens effectively neutralized and protected against multiple H3N2 influenza strains from 2014-2021 in ferret studies. The research was funded and conducted by NIAID's CIVR-HRP, allowing PDS Biotech to maintain focus on their core immuno-oncology programs, including the VERSATILE-003 Phase 3 trial for HPV-positive head and neck cancer.

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its Q1 2025 financial results conference call and webcast for May 14, 2025, at 8:00 AM ET. The company will present its financial performance for the quarter ending March 31, 2025, along with updates on its clinical programs. Investors can join via phone (1-877-704-4453 domestic, 1-201-389-0920 international) or through the webcast. The presentation will be archived on PDS Biotech's website for six months following the live event.

PDS Biotechnology (NASDAQ: PDSB) has announced the acceptance of three abstracts featuring Versamune® HPV (PDS0101) for presentation at the 2025 ASCO Annual Meeting in Chicago from May 30-June 3, 2025.

The presentations include:

• VERSATILE-003: A Phase 3 randomized trial comparing PDS0101 and Pembrolizumab vs. Pembrolizumab alone for first-line treatment of HPV16-positive recurrent/metastatic head and neck cancer
• VERSATILE-002: Results on overall survival in HPV16 positive recurrent/metastatic head and neck cancer patients treated with PDS0101 and Pembrolizumab
• MC200710: Initial results of PDS0101 alone or with pembrolizumab in locally advanced HPV-associated oropharyngeal carcinoma

PDS Biotechnology (Nasdaq: PDSB) announced that preclinical immune response data for their novel Infectimune®-based flu vaccine will be presented at the IMMUNOLOGY2025™ Annual Meeting in Honolulu, Hawaii, from May 3-7, 2025.

The presentation, titled 'Broadly Protective Immunity against Influenza and Opportunities for Universal Influenza Vaccines,' will be delivered by Dr. Andrea Sant from the University of Rochester Medical Center during the International Society of Influenza and Other Respiratory Viruses Symposium on May 4, 2025.

Additionally, the company announced the withdrawal of an abstract titled 'Alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy' from the American Association for Cancer Research Annual Meeting 2025 due to new NIH policies regarding employee attendance at scientific conferences.

PDS Biotechnology (NASDAQ: PDSB), a late-stage immunotherapy company, announced that the National Cancer Institute (NCI) will present clinical data on PDS01ADC, their IL-12 fused antibody drug conjugate, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.

The presentation, scheduled for April 29, 2025, will focus on alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy. The poster session, titled 'Immune Response to Therapies,' will be presented by Meghali Goswami, Postdoctoral Fellow at The National Institutes of Health.

PDS Biotech (PDSB) has reported its full year 2024 financial results and provided clinical program updates. The company has initiated the VERSATILE-003 Phase 3 clinical trial evaluating Versamune® HPV in HPV16-positive head and neck cancer, designed to include approximately 350 patients. The trial received FDA Fast Track designation.

Financial highlights for 2024 include a net loss of $37.6 million ($1.03 per share), compared to $42.9 million in 2023. Research and development expenses decreased to $22.6 million from $27.8 million, while general and administrative expenses reduced to $13.8 million from $15.3 million. The company's cash balance as of December 31, 2024, stood at $41.7 million.

In March 2025, PDS Biotech received FDA clearance for its IND application combining Versamune® MUC1 and PDS01ADC to treat MUC1-positive metastatic colorectal carcinoma. The company also secured up to $22 million through a registered direct offering in February 2025.